REGENTIS BIOMATERIALS LTD.

20-F supplemental

20-F

Pre-IPO filing captured from the SEC submission timeline.

Follows 424B3 in the pre-IPO sequence.

2026-02-24 · 0001213900-26-019917

424B3 priced

Final prospectus

Final prospectus filed near launch with final deal terms.

Follows CERT and confirms the priced prospectus.

Price $8.00 · 1,250,000 shares · Gross proceeds $10,000,000

Ordinary Shares, no par value · Exchange NYSE American · Ticker RGNT · Over-allotment 187,500 · Use of proceeds for working capital and general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-12-04 · 0001213900-25-118362

CERT inactive

CERT

Pre-IPO filing captured from the SEC submission timeline.

Follows FWP in the pre-IPO sequence.

2025-12-03 · 0001143313-25-000093

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds General corporate purposes · Flags foreign_private_issuer, emerging_growth_company · Underwriters ThinkEquity

2025-10-24 · 0001213900-25-101900

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation, and general corporate purposes. · Underwriters ThinkEquity LLC

2025-10-24 · 0001213900-25-101902

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares of Regentis Biomaterials Ltd. · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation settlements, and working capital. · Underwriters ThinkEquity LLC

2025-10-06 · 0001213900-25-096296

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior 8-A12B filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-09-30 · 0001213900-25-093302

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior FWP filing.

2025-09-09 · 0001213900-25-085690

8-A12B effective

Exchange Act registration

Registration filed to list the securities under the Exchange Act ahead of trading.

Follows F-1/A and registers the class of securities for exchange listing.

2025-09-09 · 0001213900-25-086109

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds working capital · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-07-07 · 0001213900-25-061821

FWP supplemental

Free writing prospectus

Prospectus supplement or marketing filing that often updates active offering terms.

Follows F-1/A and supplements the active offering with updated prospectus details.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds Proceeds will be used for clinical development, PMA submission, operations, R&D, EU marketing, loan repayment, deferred compensation, litigation settlement, and working capital. · Underwriters ThinkEquity LLC

2025-07-07 · 0001213900-25-061829

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Use of proceeds for general corporate purposes · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-05-19 · 0001213900-25-045479

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Price $11.00 · Range $10.00 to $12.00 · 1,000,000 shares · Gross proceeds $11,000,000

Ordinary Shares · Exchange NYSE American · Ticker RGNT · Over-allotment 150,000 · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-05-05 · 0001213900-25-039589

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Price $11.00 · Range $10.00 to $12.00 · 909,090 shares

Ordinary Shares · Exchange Nasdaq Capital Market · Ticker RGNT · Over-allotment 136,364 · Flags foreign_private_issuer · Underwriters ThinkEquity

2025-03-11 · 0001213900-25-022350

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

2025-02-12 · 0001213900-25-012299

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Regentis Biomaterials Ltd. is conducting a firm commitment initial public offering (IPO) of ordinary shares, aiming to raise capital for its orthopedic tissue repair solutions. The company's lead product, GelrinC, is a cell-free hydrogel designed to regenerate knee cartilage and has received CE marking in Europe. The IPO price range is unspecified, and the company plans to list on the Nasdaq Capital Market under the symbol RGNT. Regentis is an emerging growth company subject to reduced reporting requirements and faces risks related to market acceptance, regulatory approvals, and clinical trial outcomes.

2025-01-27 · 0001213900-25-006676

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after DRS.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of ordinary shares, focusing on its GelrinC product for knee cartilage repair. The company aims to list on the Nasdaq Capital Market under the symbol RGNT. The IPO involves underwriters like ThinkEquity, with an estimated price range and potential proceeds for product development and commercialization. The offering is subject to regulatory approvals and market conditions.

2025-01-24 · 0001213900-25-006245

RW withdrawn

Withdrawal request

Issuer requested withdrawal of the registration statement.

Follows F-1/A and ends the active registration process.

Regentis Biomaterials Ltd. has withdrawn its initial public offering (IPO) registration statement (Form F-1) with the SEC, citing the decision to abandon the offering. The company previously filed an amended registration statement (F-1/A) in December 2022, but now seeks to withdraw it under Rule 477(a) of the Securities Act, as no securities have been sold and the registration was never declared effective.

2024-11-21 · 0001213900-24-101083

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

Begins the tracked draft filing sequence after RW.

Regentis Biomaterials Ltd. has filed a new F-1 registration statement for an initial public offering (IPO) of ordinary shares, following a previous withdrawal request (RW) in 2024. The company, an emerging growth company and foreign private issuer, aims to list on Nasdaq under the symbol RGNT. The offering includes ordinary shares with an estimated price range, underwriting discounts, and a potential over-allotment option. The filing highlights risks related to market acceptance, regulatory approvals, and dependence on a single product candidate, GelrinC, for orthopedic tissue repair.

2024-11-21 · 0001213900-24-101093

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1/A filing.

2,022 shares

Ordinary Shares · Exchange Nasdaq Capital Market · Ticker RBTI · Units consisting of Ordinary Shares and Warrants · Warrants exercisable at 100% of IPO price, expiring 5 years from issuance · Use of proceeds General corporate purposes · Flags foreign_private_issuer, emerging_growth_company · Underwriters Maxim Group LLC

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel-based treatment for knee cartilage injuries. The offering aims to raise up to $15 million, with shares and warrants to be listed on the Nasdaq Capital Market. The filing includes details on underwriting, risks, and the company's financial and operational structure.

2022-12-19 · 0001213900-22-080923

F-1/A amended

Amended foreign registration statement

Updated foreign registration statement filed after SEC comments or deal changes.

Updates the prior F-1 filing.

Regentis Biomaterials Ltd., an Israeli regenerative medicine company, is conducting an initial public offering (IPO) to raise $15 million through the sale of units consisting of ordinary shares and warrants. The company focuses on orthopedic treatments using its Gelrin platform, a degradable hydrogel for tissue regeneration. Its lead product, GelrinC, is approved in Europe but lacks strategic partners for commercialization. The IPO is conditional on Nasdaq listing approval, and the company is an emerging growth company subject to reduced reporting requirements.

2022-12-07 · 0001213900-22-078151

F-1 filed

Initial foreign registration statement

Initial public filing for a foreign issuer submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

2,022 shares

ordinary share · Exchange Nasdaq Capital Market · Ticker AND · Units consisting of one ordinary share and one warrant to purchase one ordinary share · Warrants to purchase ordinary shares at an exercise price of $ per share, exercisable immediately and expiring five years from issuance · Flags foreign_private_issuer, units · Underwriters Maxim Group LLC

Regentis Biomaterials Ltd. is conducting its initial public offering (IPO) to raise capital through the issuance of units consisting of ordinary shares and warrants. The company, incorporated in Israel, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel-based treatment for knee cartilage injuries. The offering includes a public offering price range, underwriting discounts, and proceeds to the company. The filing highlights risks related to regulatory approvals, product development, and market competition. The company is an emerging growth company and a foreign private issuer, subject to reduced reporting requirements.

2022-11-04 · 0001213900-22-069365

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants. The offering aims to raise capital for product development and commercialization, with an estimated public offering price per unit between $ and $. The company, an emerging growth company and foreign private issuer, is focused on orthopedic treatments using its Gelrin platform for cartilage regeneration. The IPO includes a provision for underwriters to purchase additional shares or warrants to cover over-allotments.

2022-09-23 · 0001213900-22-058342

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS/A filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units comprising ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company and foreign private issuer, is seeking to list its ordinary shares on the Nasdaq Capital Market. The offering includes a structured pricing range, underwriting discounts, and a potential over-allotment option. The prospectus highlights risks related to regulatory approvals, market competition, and reliance on its lead product candidate, GelrinC, which is CE-marked but requires strategic partnerships for commercialization.

2022-08-22 · 0001213900-22-050139

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Regentis Biomaterials Ltd. is conducting an initial public offering (IPO) of units consisting of ordinary shares and warrants to purchase ordinary shares. The company, an emerging growth company and foreign private issuer, focuses on developing regenerative medicine solutions, particularly GelrinC, a hydrogel for knee cartilage repair. The offering is subject to regulatory approvals, and the company plans to list its shares on Nasdaq. The filing includes underwriting details, risk factors, and legal disclosures.

2022-07-22 · 0001213900-22-040885

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

Regentis Biomaterials Ltd. is conducting its initial public offering (IPO) to raise capital through the sale of units consisting of ordinary shares and warrants. The company, incorporated in Israel, focuses on regenerative medicine solutions using its Gelrin platform for orthopedic tissue repair. Its lead product, GelrinC, is a hydrogel implant for knee cartilage injuries, approved in Europe with a CE mark. The IPO aims to fund commercialization efforts, with shares and warrants listed on Nasdaq. The offering includes a 45-day option for underwriters to cover over-allotments. The company is an emerging growth company with reduced reporting requirements.

2022-03-29 · 0001213900-22-015639

REGENTIS BIOMATERIALS LTD.

Filing Timeline

3 comparable deals

Recent News